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The herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) promoter 1 (LP1) is the only viral promoter
that exhibits detectable transcriptional activity during a latent HSV infection. The LAT promoter-binding factor (LPBF)
regulatory sequence (nucleotides 065 to072 relative to the transcriptional start site of the 8.3-kb primary transcript) closely
resembles the core recognition sequence required for binding members of the upstream stimulatory factor (USF)/major
late transcription factor (MLTF) family. In this analysis, we demonstrate that oligonucleotides containing either the LPBF
recognition sequence or the USF/MLTF recognition sequences from previously described promoters bind cellular factors
which exhibit very similar mobilities in electrophoretic mobility shift (EMS) analyses. We also observe a high degree of
similarity in competition profiles obtained in competition EMS analyses utilizing oligonucleotides containing recognition
sequences for either LPBF or USF/MLTF. Furthermore, antibody supershift EMS analyses have demonstrated that the
factors binding the LPBF or USF/MLTF recognition sites in these oligonucleotides are antigenically related, if not identical,
and that greater than 90% of the LPBF-binding activity is antigenically related to USF. In addition, we demonstrate that both
forms of in vitro-translated USF proteins (43 and 44 kDa) bind to the LPBF recognition sequence within HSV-1 LP1. Taken
together, these data indicate that USF is capable of binding to the HSV-1 LPBF recognition sequence and that USF is a
major LPBF-binding activity in cells of neuronal and nonneuronal lineage. These data further support the hypothesis that
USF may indeed play a significant role in the transcriptional activity of HSV-1 LP1. q 1997 Academic Press
To identify viral gene products potentially involved in scripts may be involved in the establishment or reactiva-
the regulation of herpes simplex virus type 1 (HSV-1) tion of latent viral infection.
latency, experimental animals infected with the virus The HSV-1 LAT promoter 1 (LP1) is located immedi-
have been examined for transcriptional activity of the ately upstream of the 5* end of the 8.3-kb primary LAT
latent viral genome (11, 13, 20, 22, 53–56). These analy- transcript and approximately 660-bp upstream of the 5*
ses have identified transcriptional activity in very limited end of the smaller, more stable LAT transcripts (3, 14,
regions of the viral genome during the latent state. The 16, 63 – 65). A similar organization is found in the HSV-
result of transcription in these regions is the production 2 LAT promoter (33, 34). Both the HSV-1 and the HSV-2
of an 8.3-kb primary latency-associated transcript (LAT; LPs exhibit cell-type specificity in transient expression
16, 53, 64). At least three abundant and stable, nonpoly- analyses in which the promoter shows greater basal
adenylated, smaller LATs of approximately 1.45, 1.5, and activity in cells of neuronal origin than in those of non-
2.0 kb are putatively derived by alternative splicing of the neuronal origin (3, 32 – 34, 37, 64). At least two regions
primary transcript (Fig. 1A; 43, 51, 53, 59, 60). Although of HSV-1 LP1 appear to be important in the observed
a number of open reading frames have been identified cell-type specificity. The CRE-2 sequence (nucleotides
in LAT, no LAT-encoded protein products have yet been 075 to 083) confers a three- to five-fold increase in
detected during the course of productive or latent infec- promoter activity in the mouse neuroblastoma cell line
tion. A number of investigators have generated recombi- C1300 (Fig. 1B; 32). A second, more diffuse region of
nant viruses devoid of various parts of the regulatory the promoter also confers cell-type specificity. This re-
and/or coding regions of the LAT gene (6, 7, 15, 16, 26, gion has been reported as nucleotides 0161 to 0283
28, 29, 35, 38, 40, 46, 52, 57). In general, experimental (65) and 0212 to at least 0348 (32) in C1300 cells and
results utilizing these viruses suggest that the LAT tran- nucleotides 0143 to 0158 and 0177 to 0251 in the
human neuroblastoma cell line IMR-32 (4). Although
1 Current address: Human Genome Sciences, 9410 Key West Ave- LP1 may be regulated in a cell-type specific manner
nue, Rockville, MD 20850. (4, 32, 64, 65), it also contains a number of common2 These authors contributed equally to this work.
eukaryotic promoter elements (Fig. 1B). These include3 To whom correspondence and reprint requests should be ad-
dressed. Fax: (717) 531-5580. E-mail: bwigdahl@bcmic.hmc.psu.edu. a TATA box, two cyclic AMP response elements (CREs),
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FIG. 1. Relative location of the USF/MLTF recognition sequences in the HSV-1 LP1. (A) The diagram illustrates the overall organization of the
HSV-1 genome. UL , US , TRL , TRS , IRL , and IRS denote sequences corresponding to the unique-long, unique-short, terminal repeat-long, terminal
repeat-short, inverted repeat-long, and inverted repeat-short components of the HSV-1 genome, respectively. Also shown is an expanded view of
the internal repeats and messenger RNAs of several genes important in viral gene regulation encoded in this region. These include ICP0, ICP4,
ICP34.5, the primary 8.3-kb transcript, and the smaller LATs. (B) Common eukaryotic transcription factor DNA-binding consensus sites within LP1
are shown. The start site of LAT transcription is shown as /1. (C) The sequence of the LPBF-binding site and surrounding sequences are shown
from nucleotide 080 to 057. The sequence is compared to those of three previously described USF/MLTF-binding sites. These are the murine p53
regulatory region (p53; nucleotides /61 to /84), the adenovirus major late promoter (nucleotides 071 to 048), and the rat alcohol dehydrogenase
promoter (nucleotides 072 to 049).
a CCAAT box, and two Sp1 DNA-binding consensus LAT promoter template (42). Some recent in vivo evi-
dence supports the possibility that the LPBF and/orsequences (32, 36, 61). The promoter-proximal CRE,
designated CRE-1, includes nucleotides 039 to 045 CRE-1 recognition sites play functional roles in regulat-
ing LAT transcription during viral latency (50), but theseand is responsive to changes in the intracellular con-
centration of cAMP elicited by treatment with dibutyryl studies do not address the nature of the DNA-binding
activities which function through the LPBF site or CRE-cAMP or forskolin (33). The promoter-distal CRE, desig-
nated CRE-2, includes nucleotides 075 to 083 and is 1 site during latency. The core of the LPBF sequence,
5*-CACGTG-3*, is commonly referred to as the E-boxcurrently under investigation with respect to its func-
tional properties. Zwaagstra and co-workers utilized motif, and the sequence has been shown to confer
binding to a class of transcription factors of the basicelectrophoretic mobility shift (EMS), DNase I footprint,
and transient expression analyses to identify a LAT helix – loop – helix leucine zipper (bHLH-Zip) family
which includes USF/MLTF factors as well as additionalpromoter-binding factor (LPBF) recognition sequence
which is located just downstream of CRE-2 and in- c-myc-related regulatory proteins. We have previously
utilized EMS analyses (32) to demonstrate that the se-cludes nucleotides 065 to 072 of LP1 (Fig. 1C; 65). It
was suggested that a factor(s) which interacts with the quence 5*-CCACGTGG-3* (HSV-1 LP1 nucleotides 065
to 072) is sufficient in the context of a non-HSV DNALPBF recognition sequence might be related to up-
stream stimulatory factors (USF), also known as major oligonucleotide to bind a factor(s) with similar mobility
to the LPBF factor(s). Although the CRE-2 and LPBFlate transcription factors (MLTFs; 44). Additional stud-
ies have also demonstrated that HeLa cell extracts en- recognition sequences are adjacently located in LP1,
the LPBF factor(s) and members of the ATF/CREB familyriched in USF activity can stimulate transcription of a
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can bind independently to the LPBF and CRE-2 recogni-
tion sites of HSV-1 LP1 (32). However, the two groups
of proteins may function in concert to regulate LP1 ac-
tivity.
We present evidence in this report demonstrating that
both the 43- and the 44-kDa forms of USF can interact
with the LPBF recognition sequence in the HSV-1 LP1.
Since we demonstrated in previous studies (32) that con-
structs which contain only nucleotides /1 to 074 of the
HSV-1 LP (that is, contain the LPBF sequence, but do not
contain the CRE-2 recognition sequence) do not exhibit a
large degree of cell-type specificity, it seems unlikely that
the LPBF recognition sequence is singly involved in the
cell-type specificity of the promoter. However, the LPBF
recognition sequence may play an important role as a
basal regulatory element within HSV-1 LP1 by binding
cell-type common factors such as USF. In this model,
USF may influence the neuronal activity of LP1 conferred
by neuronal-specific or induced factors.
EMS analyses were utilized to examine relative mobili-
ties of DNA–protein complexes formed between nuclear
extracts and oligonucleotides containing the LPBF recog-
nition sequence or previously identified USF/MLTF rec-
ognition sequences from several cellular promoters (Fig.
1C). In these experiments, the LPBF recognition se- FIG. 2. EMS analyses comparing mobilities of DNA–protein com-
quence was compared to the USF/MLTF recognition se- plexes formed utilizing oligonucleotides containing an LPBF recognition
sequence and several USF/MLTF recognition sequences. EMS analy-quence located in the murine p53 tumor-suppressor
sis was performed as previously described (32) using probes K54/74,gene (41), adenovirus major late promoter (Ad-MLP; 8),
p53, Ad-MLP, and RAD reacted with L929 and C1300 nuclear extracts.
or rat class I alcohol dehydrogenase gene (RAD; 39). The migration of free probe DNA is indicated by FP. Lanes 1–4 and
Oligonucleotide K54/74 includes the LPBF recognition 5–8 show the DNA–protein complex formed when the indicated probes
sequence of HSV-1 LP1 (nucleotides 054 to 074). Previ- and L929 and C1300 nuclear extracts, respectively, are reacted. The
mobility of the most abundant DNA–protein complex formed with eachous studies have demonstrated that the eight-nucleotide
probe is indicated by LPBF/USF/MLTF. Oligonucleotides used assequence 5*-CCACGTGG-3* (nucleotides 065 to 072 of
probes in all EMS analyses were synthesized by the Macromolecular
HSV-1 LP1) when flanked by non-HSV DNA was sufficient Core Facility, The Pennsylvania State University College of Medicine
to produce a single, highly abundant DNA–protein com- (Hershey, PA). Double-stranded oligonucleotides used in EMS analyses
plex with a very similar, if not identical, mobility to that were generated by combining equimolar amounts of single-stranded,
complementary oligonucleotides. The mixtures were denatured for 10of a putative LPBF-containing DNA–protein complex pro-
min at 95–1007 and annealed by cooling slowly to room temperatureduced with nucleotides 054 to 094 (32). Furthermore,
(approximately 2 hr). Nuclear protein extracts were prepared as de-
this recognition sequence (nucleotides 065 to 072) very scribed (32). Oligonucleotides containing HSV-1 LP1 sequences were
closely matches the core consensus DNA-binding site labeled with [a-32P]dCTP by the Klenow fragment of DNA polymerase
for USF/MLTF (17, 21). As a result, we were interested I. Labeled probe (60,000 cpm) was incubated with 7 mg of nuclear
extract and 2 mg poly(dI-dC) for 20 min at 307. Reactions were subjectedin determining if factors which interact with the LPBF
to electrophoresis in a 4% polyacrylamide gel at 30 mA, dried at 807recognition sequence include USF. To this end, we gen-
for 90 min, and subjected to autoradiography from 8 to 24 hr at 0807.
erated a series of oligonucleotide probes, each of which
contains a USF/MLTF recognition sequence from an un-
related promoter element. We utilized these oligonucleo- were very similar, if not identical (Fig. 2, compare lane 1
to 2–4 and lane 5 to 6–8). This observation suggeststide probes in EMS analyses to compare DNA–protein
complex formation between the HSV-1 LPBF recognition that the same or very closely related protein or protein
complex is involved in formation of the LPBF- and USF/sequence and known USF/MLTF recognition sequences
(Fig. 2). When reacted with nuclear extract prepared from MLTF-containing DNA–protein complexes.
With the exception of a single guanosine to adenosineeither C1300 or L929 cells, the LPBF recognition se-
quence probe (054 to 074) and each of the unrelated base change in the RAD promoter oligonucleotide, the
USF/MLTF core recognition sequence (5*-CACGTG-3*)USF/MLTF recognition sequence probes generated a
single, highly abundant DNA–protein complex, as well in each of the four oligonucleotides is identical (Fig. 1C).
This observation, coupled with the fact that flanking se-as several less abundant DNA–protein complexes. The
relative mobilities of the DNA–protein complexes formed quences of three known USF/MLTF-binding sites and
those of the LPBF-binding site are rather dissimilar,with the LPBF and USF/MLTF recognition sequences
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prompted us to examine relative binding specificities of the oligonucleotides containing a USF/MLTF recognition
sequence (Fig. 4A). With exception of the reaction of theproteins involved in formation of the single highly abun-
dant DNA–protein complex. Oligonucleotide competition Ad-MLP recognition sequence with the C1300 extract
(lane 14), the bottom half of the most abundant DNA –EMS analyses indicate that binding specificities of cellu-
lar proteins involved in formation of DNA–protein com- protein complex in each reaction appeared to be abro-
gated with addition of the anti-43-kDa USF antiserumplexes formed with LPBF (K54/74) or USF/MLTF recogni-
tion sequences (p53, Ad-MLP, and RAD) are similar but with a sizable amount of supershifted complex observed
(Fig. 4A). These results suggest the possibility that thenot identical when using either C1300 or L929 nuclear
extracts (Figs. 3A and 3B, respectively). The addition of single, highly abundant DNA–protein complex formed
with the oligonucleotide probes representing either thea 10-fold molar excess of unlabeled K54/74 or each of
the unlabeled USF/MLTF oligonucleotides to the binding LPBF or the USF/MLTF recognition sites may actually
consist of at least two DNA–protein complexes. Thesereaction resulted in only minimal competition with re-
spect to the DNA–protein complex formed with the K54/ results provide additional evidence in support of the con-
cept that the LPBF and USF/MLTF recognition sites bind74 probe. However, the addition of a 50- or 150-fold molar
excess of unlabeled K54/74 oligonucleotide effectively common factors.
A second series of supershift EMS analyses were per-abrogated the DNA–protein complex formed with the
K54/74 probe. Although the addition of a 50- or 150-fold formed to determine whether the 44-kDa form of USF
could also interact with the LPBF recognition sequence.molar excess of each unlabeled USF/MLTF-binding site
oligonucleotide also abrogated the DNA–protein com- The addition of anti-44-kDa USF antiserum to a binding
reaction containing the K54/74 oligonucleotide resultedplex formed with the K54/74 probe, the level of inhibition
observed with the same molar excess of unlabeled K54/ in a supershift of the upper region of the most abundant
DNA–protein complex (Fig. 4B, lanes 3 and 13). This74 was considerably more. The addition of a 50- or 150-
fold molar excess of the oligonucleotide containing the result is similar to that obtained when anti-43-kDa USF
antiserum was added to the binding reaction (Figs. 4A,USF/MLTF recognition sequence derived from the Ad-
MLP consistently abrogated the DNA–protein complex lanes 2 and 10; and 4B, lanes 2 and 12). The addition of
a mixture of increasing amounts of both anti-43-kDa andformed with the K54/74 probe to a lesser degree than did
the oligonucleotides containing USF/MLTF recognition anti-44-kDa USF antisera to the binding reaction resulted
in an increased abrogation and supershift of the mostsequences derived from the p53 and RAD promoters.
These results were observed when oligonucleotide abundant DNA–protein complex (Fig. 4B, lanes 4–7 and
14–17). At the point where 2 ml of each antiserum wasprobe K54/74 was reacted with nuclear extracts prepared
from either C1300 cells (Fig. 3A) or L929 cells (Fig. 3B). included in the binding reaction, greater than 90% (quan-
titated by Betagen technology) of the most abundantCompetition analyses suggest that a factor(s) present in
DNA–protein complexes formed with the three USF/ DNA–protein complex was supershifted. Control anti-
sera raised against c-Myc and N-Myc (Fig. 4B, lanes 8–MLTF recognition sequences and the LPBF-binding site
(K54/74) exhibits similar, but not identical, affinities for 9 and 18–19) were also tested to demonstrate that the
abrogation and supershifts observed with the anti-USFeach of the four target sequences.
Previous studies by other investigators (23, 49) have antisera were not due to nonspecific interactions be-
tween antisera and nuclear extracts. This result indicatesresulted in the identification of two USF proteins with
apparent molecular masses of 43 and 44 kDa, termed that a significant portion of the protein constituent of the
most abundant DNA–protein complex consists of USF-USF-1 and USF-2, respectively. USF proteins bind DNA
as either 43- or 44-kDa homodimers or as 43/44-kDa 1 (43 kDa) and USF-2 (44 kDa). These observations were
consistent in experiments which used nuclear extractsheterodimers (23, 49). To identify the protein factor(s)
interacting with the LPBF recognition sequence of the prepared from either C1300 or L929 cells indicating that
USF-1 and USF-2 appear to be capable of interactingHSV-1 LP1, we performed antibody supershift EMS anal-
yses (Fig. 4). The addition of anti-43-kDa USF antiserum with the LPBF sequence utilizing representative neuronal
and nonneuronal nuclear extracts.to the EMS binding reaction resulted in a supershift of
a large amount of the most highly abundant DNA–protein Supershift EMS analyses were performed using anti-
sera raised against Max to attempt to identify the re-complex formed when either C1300 or L929 nuclear ex-
tracts were reacted with oligonucleotide K54/74 or any of maining protein constituents of the major DNA–protein
FIG. 3. Oligonucleotide competition EMS analysis using probe K54/74 with (A) C1300 or (B) L929 nuclear extract. DNA–protein complex formation
when oligonucleotide probe K54/74 was reacted with the indicated nuclear extract in the absence of competitor oligonucleotide DNA is shown in
lane 1. Lanes 2–5, 6–9, and 10 –13 show DNA–protein complex formation in the presence of 10-, 50-, and 150-fold molar excess of the indicated
unlabeled competitor oligonucleotide. The mobilities of the LPBF/USF/MLTF DNA–protein complex and free probe (FP) DNA are also indicated.
Oligonucleotide competition EMS analyses were performed as described for Fig. 2 with the exception that the indicated nuclear extract was
incubated with competitor oligonucleotide for 20 min at 307. Labeled probe DNA was subsequently added and the reaction was incubated for an
additional 20 min at 307.
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complex that were not supershifted with either anti-43- recognition sequence as well as other USF/MLTF se-
quences. Also, since the 43- and 44-kDa USF proteinskDa or anti-44-kDa (or a combination of both anti-43-kDa
and anti-44-kDa) antisera. Max is a relatively stable DNA- have been documented to require dimerization for DNA
binding (23, 49), it is predicted that the 43- and 44-kDabinding protein that forms homodimers or heterodimers
with Myc or Mad family members to regulate transcrip- USF proteins bound to the LPBF and USF/MLTF recogni-
tion sequences as homodimers (Fig. 5, lanes 1–8) and,tion (2, 5). Because Myc and Mad family members bind
DNA poorly as homodimers (2, 12) and since Max ap- possibly as 43/44-kDa heterodimers (Fig. 5, lanes 9–
12). Furthermore, the mobilities of the in vitro-transcribedpears to play a central role in the integration of transcrip-
tional activation and repression signals by heterodimeriz- and -translated USF proteins corresponded to those of
the highly abundant, closely migrating DNA–proteining with Myc and Mad family members, the absence of
Max in a DNA–protein complex is also a strong indicator complexes formed with L929 nuclear extract (Fig. 5, lanes
13–16). The oligonucleotide which contains the Ad-MLPof the absence of any Myc- or Mad-related complexes
as well. Antiserum directed against Max was included recognition sequence interacted with the 43- or 44-kDa
forms of USF (Fig. 5, lanes 3, 7, and 11), but at muchin the binding reaction in these experiments (Fig. 4B,
lanes 10 and 20). No detectable supershift was observed lower levels than did each of the other oligonucleotides
(visualized after longer period of autoradiography; datain DNA–protein complexes formed between either
C1300 or L929 nuclear extracts and the K54/74 oligonu- not shown). This observation was also true when in vitro-
translated protein products were replaced with nuclearcleotide probe in the presence of this antiserum, which
indicates that the remaining complexes do not contain extract prepared from L929 cells (Fig. 5, compare lane
15 to lanes 13, 14, and 16). Taken together, these dataMax. The immunoreactivity of the Max antisera was con-
firmed in positive control EMS analyses using purified strongly support the hypothesis that the highly abundant,
closely migrating DNA–protein complexes formed be-Max protein (data not shown). Therefore, the residual
nonsupershifted complex most likely involves USF–DNA tween C1300 and L929 nuclear extracts and the oligonu-
cleotide probes containing the LPBF and USF/MLTF rec-complexes which were not bound by antibody; however,
it is possible that they may contain less abundant uniden- ognition sequences are indeed composed predominantly
of various combinations of the 43- and 44-kDa USF pro-tified factors which migrate like USF in EMS analyses.
Based on the results obtained in the supershift EMS teins.
Members of the USF/MLTF family are present in aanalyses, we hypothesize that the closely migrating,
highly abundant DNA–protein complexes formed from variety of cell types and bind to the core DNA sequence
5*-CACGTG-3* (9, 49). This sequence is located betweenthe interaction of the oligonucleotide probes containing
either LPBF or USF/MLTF recognition sequences and nucleotides 064 and 072 of HSV-1 LP1 and binds a
factor(s) termed the LAT promoter-binding factor or LPBFC1300 and L929 nuclear extracts are composed primarily
of USF family members. To examine the role of 43- and (32, 65). We present EMS analyses herein which demon-
strate that the LPBF factor(s) binds to an oligonucleotide44-kDa USF proteins in forming the LPBF-containing
DNA–protein complex, we performed EMS analyses uti- containing the LPBF recognition sequence, resulting in
at least two, closely migrating DNA–protein complexeslizing 43- and 44-kDa USF proteins produced in vitro. We
produced both 43- and 44-kDa USF proteins by in vitro of high abundance. The mobilities of the LPBF-containing
DNA–protein complexes are indistinguishable from thetranscription and translation of cDNA copies of the USF
coding sequences. The resulting translation products mobilities of DNA–protein complexes resulting from oli-
gonucleotides containing the murine p53, the Ad-MLP,were combined with the oligonucleotide probes con-
taining LPBF and USF/MLTF recognition sequences in or the RAD USF/MLTF recognition sequences. We also
demonstrated that a significant proportion of the proteinsstandard EMS reactions (Fig. 5). The results indicate that
both the 43- and 44-kDa proteins can bind to the LPBF involved in the formation of DNA–protein complexes with
FIG. 4. (A) Supershift EMS analysis using oligonucleotides K54/74, p53, Ad-MLP, or RAD as probe with L929 and C1300 nuclear extracts with
43-kDa USF antiserum. The most abundant LPBF/USF/MLTF DNA–protein complex is indicated by the arrow labeled LPBF/USF/MLTF. A supershift
of this DNA– protein complex obtained by the addition of anti-43-kDa antiserum is indicated by the arrow labeled Supershift. All lanes utilize the
anti-43-kDa antiserum at a dilution of 1:50. The antiserum was analyzed over a wide range of dilutions (0 to 1:10,000) to determine the optimal
supershift (data not shown). The antiserum was also tested for specificity by supershifting recombinant 43-kDa USF (data not shown). Lanes 1–8
and 9–16 are the result of reacting the indicated oligonucleotide probe with L929 and C1300 nuclear extracts, respectively. The migration of free
probe (FP) is also shown. In these analyses, rabbit polyclonal antisera were added to the binding reactions immediately prior to loading the gel.
Anti-43-kDa USF antisera were prepared as described (52, 62). (B) Supershift EMS analysis using oligonucleotides K54/74 as probe with L929 and
C1300 nuclear extracts and antisera directed against USF, c-Myc, N-myc, and Max. Lanes 2 and 12 include 2.0 ml anti-43-kDa USF antiserum.
Lanes 3 and 13 include 2.0 ml anti-44-kDa USF antiserum. Lanes 4–7 and 14–17 include 0.25 ml (lanes 4 and 14), 0.5 ml (lanes 5 and 15), 1.0 ml
(lanes 6 and 16), and 2.0 ml (lanes 7 and 17) of anti-43-kDa and anti-44-kDa USF antisera. Lanes 8 and 18 include 2.0 ml anti-c-Myc antiserum.
Lanes 9 and 19 include 2.0 ml anti-N-Myc antiserum. Lanes 10 and 20 include 2.0 ml anti-Max antiserum. The antisera raised against USF, c-Myc,
N-Myc, and Max were all rabbit polyclonals obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Experiments have also been performed
using USF antisera provided by Dr. Michele Sawadogo (M. D. Anderson Cancer Center, Houston, TX).
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FIG. 5. EMS analysis using in vitro-transcribed and -translated 43- and 44-kDa USF proteins with probe K54/74. The mobilities of the 43- and 44-
kDa forms of USF are shown. Lanes 1–4 show the resulting DNA –protein complexes when the 43-kDa protein was reacted with the indicated
oligonucleotide probes. Lanes 5 –8 show the results of reacting 44-kDa USF protein with the indicated oligonucleotide probes. Lanes 9–12 show
the results of reacting both 43- and 44-kDa USF proteins with the indicated oligonucleotide probes. Lanes 13–16 show the results of reacting L929
nuclear extract with the indicated probes. The migration of free probe (FP) is shown. Labeled probe (60,000 cpm) was incubated with 1–2 ml of
recombinant USF protein and 2 mg poly(dI-dC) for 20 min at 307. Recombinant 43- and 44-kDa USF proteins (USF-1 and USF-2, respectively) were
prepared using the TNT Coupled Wheat Germ Extract System (Promega, Madison, WI). Briefly, 25 ml of TNT wheat germ extract, 10 U RNA
polymerase, 1 mM amino acid mixture (methionine-free), 4 mCi [35S]methionine (1000 Ci/mmol), 40 U RNasin (Promega, Madison, WI), and 1 mg
USF-encoding plasmid DNAs were combined in a final volume of 50 ml and incubated at 307 for 2 hr. Plasmids pDi2-18 and pM2-2, encoding the
43- and 44-kDa forms of USF, respectively, were provided by Dr. Michele Sawadogo and have been described (23, 49). The production of protein
products of expected apparent molecular mass was confirmed by PAGE utilizing gels containing 12% polyacrylamide and 0.1% SDS (data not
shown).
the LPBF and other USF/MLTF DNA recognition se- ther USF/MLTF and LPBF recognition sequence probes
migrated differently in EMS analyses. In addition to thequences are antigenically related in that a portion of
the complexes can be supershifted with antisera raised HSV-1 LPBF-binding sequence probe (K54/74), we pro-
vided three unrelated oligonucleotide probes containingagainst the 43-kDa USF protein in supershift EMS analy-
ses. We specifically showed in the case of the LPBF USF/MLTF recognition sequences to which factors bind
resulting in DNA–protein complexes with similar, if notrecognition sequence that at least 90% of this complex
was antigenically related to both the 43- and the 44-kDa identical, mobilities. We added to these observations by
demonstrating that previously described USF/MLTF rec-USF proteins. In addition, we demonstrated that both the
43- and the 44-kDa forms of USF protein expressed in ognition sequences inhibit the formation of DNA–protein
complexes formed with the LPBF recognition sequencevitro bind to the LPBF recognition sequence of the HSV-
1 LP. Collectively, these observations indicate that mem- (Figs. 3A and 3B). Zwaagstra and co-workers (65) sug-
gested that sequences flanking the core DNA sequencebers of the USF family can bind to the LPBF recognition
sequence in the HSV-1 LP. 5*-CACGTG-3* are likely to play a role in LPBF binding,
and that the sequences flanking the LPBF site show little,Zwaagstra and co-workers originally identified the HSV-
1 LPBF recognition sequence and reported that LPBF is if any, similarity to those flanking other USF/MLTF sites.
It is likely that sequences flanking the core USF/MLTFrelated to, but distinct from, USF/MLTF factors character-
ized at that time (65). The distinction was proposed based recognition sequence influence factor binding to the site
(19, 25); however, we have demonstrated previously thaton the fact that DNA–protein complexes formed with ei-
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HSV-1 LP1 sequences flanking the LPBF-binding site may may function in concert with neuronal-specific factors
that may bind to less characterized upstream elements.be replaced with unrelated, non-HSV sequences without
In conjunction with the DNA-binding studies, we havealtering mobility of the LPBF-containing DNA–protein
utilized a 348-nucleotide LP1 CAT expression construct incomplex in EMS analysis (32).
transient expression analyses to demonstrate that muta-USF is a common eukaryotic transcription factor which
tions in the LPBF site that inhibit USF binding significantlycontains both a bHLH domain and a leucine repeat do-
inhibit basal LP1 activity in both neuronal and nonneuronalmain. It is a member of the c-myc-related family of regula-
cell types (data not shown). One would predict from suchtory proteins and can be purified from HeLa cell extracts
experiments that USF may play an important role in activat-as two polypeptides with apparent molecular weights of
ing basal LP1 activity in primary neurons as well. In fact,43 and 44 kDa (10, 44, 45). Molecular cloning of the 43-
the significance of the LPBF site in regulating LAT tran-kDa USF factor has been described (23), and the recent
scription in vivo is strengthened by recent data which showmolecular cloning of the 44-kDa USF factor from murine
that a HSV-1 LP1 mutant containing a deletion of genomiccells revealed a high degree of similarity in the dimeriza-
sequence encompassing LPBF, CRE-1, and the TATA boxtion and DNA-binding domains of USF family members
(DUCT) displays undetectable LAT transcription in CNScoupled with a high degree of variation in the N-terminal
neurons latently infected by HSV-1 as assayed by the sen-regions (49). Northern blot hybridization analyses indi-
sitive PCR technique (50). In comparison, a latent infectioncated that expression of the 43- and 44-kDa forms of
by a virus that contains inhibitory mutations in the TATAUSF mRNA appears to be ubiquitous among samples
box alone does show detectable LAT transcription andprepared from a number of different mouse tissues. How-
therefore the deletion of CRE-1 and LPBF could accountever, EMS analyses have indicated that the relative ex-
for the complete absence of LAT transcriptional activity inpression of the 43- and 44-kDa forms of USF may differ
these studies. The importance of CRE-1 in activating theat the protein level between the HeLa and S194 (mouse
LAT promoter in transiently transfected cells is well docu-B cell) cell lines (49). These results suggest that although
mented (1, 36, 40); however, evidence in vivo indicates thatexpression of USF appears to be relatively ubiquitous,
CRE-1 is not necessary for basal LAT promoter activityeither the 43- or the 44-kDa form may predominate in a
during latency (1, 40), although it may influence the kineticsgiven tissue or cell type.
of reactivation (40). The role that LPBF plays in vivo is
The suggestion that USF may be differentially ex-
unclear; however, in vitro transfection studies conducted
pressed at the protein level opens the possibility that by us (data not shown) and by Zwaagstra and co-workers
USF may be involved in the cell-type specificity of HSV- (65) indicate that LPBF may play a significant role in sup-
1 LP1. The LPBF recognition sequence of HSV-1 LP1 is porting basal LP1 activity. Although the importance of the
located just downstream of the cell-type specific CRE-2 LPBF site in vivo remains to be assessed directly, the
sequence (32). Due to their relatively close locations, activity of a factor such as USF could explain the loss of
factors interacting with the two sites may interact with LP activity in CNS neurons by the DUCT mutant strain of
each other. We demonstrated previously that both ATF/ HSV-1 (50). It has been suggested that the role of CRE
CREB and LPBF/USF factors bind to their respective rec- elements in LP1 is to regulate inducible LP1 activity during
ognition sequences independently of each other (32). the establishment or reactivation phases of HSV-1 latency
However, this observation does not preclude the possi- (1). If this is the case, then LP1 activity during latency may
bility of protein–protein interactions between ATF/CREB be most attributable to basal elements which bind factors
and USF factors subsequent to DNA binding that may such as Sp1 and USF. However, the relative importance
be important for activity of the promoter. In fact, both of basal and inducible LP1 activity during HSV-1 latency
ATF/CREB and USF interact with other cellular proteins is in need of further clarification.
involved in the transcriptional regulation of the promoters Based on the data presented in this study, we con-
with which these proteins interact (17, 24, 31, 62). USF clude that both the 43- and the 44-kDa forms of USF bind
factors may be differentially expressed at the RNA or to the LPBF-binding site in the HSV-1 LP1 in a variety of
protein levels in C1300 and L929 cells. If this possibility in vitro DNA-binding analyses. It does, however, remain
were the case, the result may be the preferential forma- possible that additional bHLH-Zip proteins may function-
tion of one of the three or more possible USF dimers in ally interact with the LPBF-binding site since we have
the two cell types. As a result of differential USF dimer evidence that purified TFEB and Max proteins are capa-
composition between cell types, their potential interac- ble of binding to this site in vitro (data not shown). It
tions with ATF/CREB factors may influence the identity must be noted that we could find no evidence for a signifi-
of factors which interact with the HSV-1 LP1 CRE-2 site. cant LPBF-binding activity other than USF in the crude
Thus, USF factors bound to the LPBF site may play a nuclear extracts prepared from the cell lines used in
role in determining which ATF/CREB factors will interact the experiments presented in this report. This includes
with the HSV-1 LP1 CRE-2 site, and indirectly influence nuclear extracts prepared from C1300 cells stimulated
the cell-type specific transcriptional regulation of the pro- with dibutyryl cAMP, forskolin, and ionomycin, all of
which show invariable LPBF binding under conditionsmoter. It is also possible that USF factors bound to LPBF
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